Patient Care Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Patient Care Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Meningococcal Vaccines
Scientists at Center for Infections describe research in meningococcal vaccines
January 7th, 2007
Data detailed in "Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom" have been presented. "The meningococcal serogroup C conjugate (MCC) vaccine was introduced into the United Kingdom with licensure based on immunogenicity data not efficacy data. All subjects with laboratory-confirmed meningococcal serogroup C (MenC) disease from January 2000 to December 2003 in U.K. and Wales were followed up," researchers in Manchester, the United Kingdom report. "A vaccine failure was defined as a laboratory-confirmed case of MenC disease occurring >or=10 days after the subject's last scheduled dose of MCC vaccine. Total...
Source: Patient Care Law Weekly (2007-01-07)
|
